TLR7/9 Antagonist Reduces HIV-1-induced Immune Activation

Retrovirology - United Kingdom
doi 10.1186/1742-4690-9-s2-p172
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia

Cancer Research
Cancer ResearchOncology
2018English

Immune Activation and HIV

Current Opinion in HIV and AIDS
VirologyOncologyInfectious DiseasesImmunologyHematology
2016English

HIV-associated Chronic Immune Activation

Immunological Reviews
AllergyImmunology
2013English

Immune Activation and HIV Persistence

Current Opinion in HIV and AIDS
VirologyOncologyInfectious DiseasesImmunologyHematology
2013English

Immune Activation With HIV Vaccines

Science
MultidisciplinaryPhilosophy of ScienceHistory
2014English

Blocking Type I Interferon Production: A New Therapeutic Option to Reduce the HIV-1-Induced Immune Activation

Clinical and Developmental Immunology
2012English

CD4-Induced Activation in a Soluble HIV-1 Env Trimer

Structure
Structural BiologyMolecular Biology
2014English

VEGFR-1 Activation-Induced MMP-9-dependent Invasion in Hepatocellular Carcinoma

Future Oncology
MedicineCancer ResearchOncology
2015English

Humanized Mice as a Useful Model to Study HIV-1 Induced Immune Activation, Its Mechanisms and Potential Therapeutic Approaches

Retrovirology
VirologyInfectious Diseases
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy